Immune checkpoints A therapeutic target in triple negative breast cancer

被引：35

作者：

Chawla, Akhil ^{[1
]}

Philips, Anne V. ^{[1
]}

Alatrash, Gheath ^{[2
]}

Mittendorf, Elizabeth ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplant & Cellular Therapy, Houston, TX 77030 USA

来源：

ONCOIMMUNOLOGY | 2014年 / 3卷 / 04期

关键词：

PD-L1; PI3K; triple negative breast cancer; biomarker; immunotherapy; IMMUNOTHERAPY; ANTIBODY; SAFETY;

D O I：

10.4161/onci.28325

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

引用

页数：3

共 50 条

[31] SRC as a novel therapeutic target fot the treatment of triple negative breast cancer (TNBC)
Walsh, S.
Tryfonopoulos, D.
Quinn, C.
Flanagan, L.
Pierce, A.
McDermott, E. W.
Evoy, D.
O'Donovan, N.
Crown, J.
Duffy, M. J.
BRITISH JOURNAL OF SURGERY, 2011, 98 : 25 - 26
[32] CDC20 is a novel therapeutic target in triple-negative breast cancer
Sharma, Jayesh K.
Alluri, Prasanna
Udden, Nashir
CANCER RESEARCH, 2020, 80 (16)
[33] Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer
Liao, Chengheng
Zhang, Yang
Fan, Cheng
Herring, Laura E.
Liu, Juan
Locasale, Jason W.
Takada, Mamoru
Zhou, Jin
Zurlo, Giada
Hu, Lianxin
Simon, Jeremy M.
Ptacek, Travis S.
Andrianov, Victor G.
Loza, Einars
Peng, Yan
Yang, Huanghe
Perou, Charles M.
Zhang, Qing
CANCER DISCOVERY, 2020, 10 (11) : 1706 - 1721
[34] SIGNIFICANCE OF C-MET AS A THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER
Kashiwagi, S.
Yashiro, M.
Aomatsu, N.
Kawajiri, H.
Takashima, T.
Onoda, N.
Ishikawa, T.
Hirakawa, K.
ANNALS OF ONCOLOGY, 2012, 23 : 84 - 84
[35] NOTCH4 Is a Potential Therapeutic Target for Triple-negative Breast Cancer
Nagamatsu, Iori
Onishi, Hideya
Matsushita, Shojiro
Kubo, Makoto
Kai, Masaya
Imaizumi, Akira
Nakano, Kenji
Hattori, Masami
Oda, Yoshinao
Tanaka, Masao
Katano, Mitsuo
ANTICANCER RESEARCH, 2014, 34 (1A) : 69 - 80
[36] LRP5: a potential therapeutic target in triple-negative breast cancer
Maubant, Sylvie
Maire, Virginie
Tesson, Bruno
Gentien, David
Marty-Prouvost, Berengere
Cruzalegui, Francisco
Depil, Stephane
Tucker, Gordon C.
Roman-Roman, Sergio
Dubois, Thierry
CANCER RESEARCH, 2013, 73 (08)
[37] PIM1 MAY BE A THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER
不详
CANCER DISCOVERY, 2016, 6 (12) : 1303 - 1303
[38] ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
Chao Xu
Yongjie Xie
Peng Xie
Jianming Li
Zhongsheng Tong
Yanfang Yang
Discover Oncology, 14
[39] ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
Xu, Chao
Xie, Yongjie
Xie, Peng
Li, Jianming
Tong, Zhongsheng
Yang, Yanfang
DISCOVER ONCOLOGY, 2023, 14 (01)
[40] IGFR as a candidate therapeutic target for cancer-initiating cells in triple-negative breast cancer
Ueno, Naoto T.
Kai, Kazuharu
MOLECULAR CANCER RESEARCH, 2013, 11

← 1 2 3 4 5 →